Caricamento...
Reappraising antiangiogenic therapy for breast cancer
Phase III trials of antiangiogenic drugs for metastatic breast cancer have either had only limited success, e.g. the monoclonal anti-VEGF antibody bevacizumab when used with various conventional chemotherapy regimens, or have failed altogether, e.g. the small molecule oral tyrosine kinase inhibitor...
Salvato in:
| Pubblicato in: | Breast |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2011
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4540338/ https://ncbi.nlm.nih.gov/pubmed/22015294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0960-9776(11)70295-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|